Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage temozolomide for prior temozolomide responders.
Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Franceschi E, et al. Among authors: lassman ab. Cancer. 2005 Dec 1;104(11):2473-6. doi: 10.1002/cncr.21564. Cancer. 2005. PMID: 16270316 Free article.
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Carneiro BA, Papadopoulos KP, Strickler JH, Lassman AB, Waqar SN, Chae YK, Patel JD, Shacham-Shmueli E, Kelly K, Khasraw M, Bestvina CM, Merrell R, Huang K, Atluri H, Ansell P, Li R, Jin J, Anderson MG, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Aristide MRN, Gan HK. Carneiro BA, et al. Among authors: lassman ab. Neurooncol Adv. 2022 Dec 21;5(1):vdac183. doi: 10.1093/noajnl/vdac183. eCollection 2023 Jan-Dec. Neurooncol Adv. 2022. PMID: 36814898 Free PMC article.
What is a glioblastoma?
Lassman AB, van den Bent MJ. Lassman AB, et al. Neuro Oncol. 2023 Jun 2;25(6):1015-1016. doi: 10.1093/neuonc/noad044. Neuro Oncol. 2023. PMID: 36789896 Free PMC article. No abstract available.
Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states.
Al-Dalahmah O, Argenziano MG, Kannan A, Mahajan A, Furnari J, Paryani F, Boyett D, Save A, Humala N, Khan F, Li J, Lu H, Sun Y, Tuddenham JF, Goldberg AR, Dovas A, Banu MA, Sudhakar T, Bush E, Lassman AB, McKhann GM, Gill BJA, Youngerman B, Sisti MB, Bruce JN, Sims PA, Menon V, Canoll P. Al-Dalahmah O, et al. Among authors: lassman ab. Nat Commun. 2023 May 4;14(1):2586. doi: 10.1038/s41467-023-38186-1. Nat Commun. 2023. PMID: 37142563 Free PMC article.
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Ellingson BM, Wen PY, Chang SM, van den Bent M, Vogelbaum MA, Li G, Li S, Kim J, Youssef G, Wick W, Lassman AB, Gilbert MR, de Groot JF, Weller M, Galanis E, Cloughesy TF. Ellingson BM, et al. Among authors: lassman ab. Neuro Oncol. 2023 Jun 2;25(6):1017-1028. doi: 10.1093/neuonc/noad002. Neuro Oncol. 2023. PMID: 36617262 Free PMC article.
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC. Lassman AB, et al. Clin Cancer Res. 2005 Nov 1;11(21):7841-50. doi: 10.1158/1078-0432.CCR-05-0421. Clin Cancer Res. 2005. PMID: 16278407 Clinical Trial.
Response of glioblastomas to EGFR kinase inhibitors.
Lassman AB, Abrey LE, Gilbert MR. Lassman AB, et al. N Engl J Med. 2006 Feb 2;354(5):525-6; author reply 525-6. doi: 10.1056/NEJMc053459. N Engl J Med. 2006. PMID: 16452568 No abstract available.
150 results